

Application News

Liquid Chromatography Mass Spectrometry

High-Speed Analysis of Voriconazole in Plasma Using Triple Quadrupole LC/MS/MS (LCMS-8050)

No.C125

Voriconazole is a triazole antifungal agent that is used widely for the treatment of infections by fungi of the genus Aspergillus and Candida.

This article introduces an example of high-speed analysis of voriconazole in plasma using the LCMS-8050 high-sensitivity triple quadrupole mass spectrometer. Although a simple method of sample pretreatment was used that involves only deproteinization, the quantitative results obtained were excellent in terms of accuracy and precision.




Fig. 1 Structural Formula of Voriconazole

Sample Pretreatment

The pretreatment workflow is shown in Fig. 2. Standard (STD) samples with concentration of 0.1, 0.5, 1, 2.5, 5, and 10 µg/mL in plasma were prepared to create a calibration curve, and QC samples with concentration of 0.2, 4, and 8 µg/mL in plasma were prepared to validate the analysis results. An internal standard solution and acetonitrile were added to these standard samples and QC samples, and the deproteinized supernatant was then used for analysis. The stable isotope-labeled compound of voriconazole (voriconazole-d3) was used as the internal standard solution.

The pretreatment method used is simple and requires no labor-intensive steps such as solid phase extraction, which allows pretreatment to be performed at low cost and in a short period of time.




Fig. 2 Pretreatment Workflow

LC/MS/MS Analytical Conditions

LC/MS/MS analytical conditions are shown in Table 1, and MRM transitions are shown in Table 2. A Shimpack GIS column was used, and separation was performed in reverse-phase mode. Electrospray ionization (ESI) was used as the method of ionization, and MRM measurements were performed in positive ion mode.

Table 2 MRM Parameters

Compound Name	Polarity	MRM Transition
Voriconazole	+	350.20 > 281.20
Voriconazole-d3	+	353.20 > 284.20

Table 1 Analytical Conditions

Shim-pack GIS (75 mm L. \times 2.1 mm I.D., 3 μ m) Column Mobile Phase A) 10 mmol/L Ammonium acetate in water B) Methanol

Time Program B.Conc. 30 % (0 - 0.50 min) \rightarrow 100 % (1.50 - 3.00 min) \rightarrow 30 % (3.01 - 5.00 min)

Flowrate Column Temperature 0.4 mL/min 40 °C

Injection Volume +4.0 kV (ESI-positive mode) Probe Voltage

DL Temperature 250 °C 400 °C 300 °C Block Heater Temperature Interface Temperature 3 L/min Nebulizing Gas Flow Drying Gas Flow 10 L/min 10 L/min

Heating Gas Flow

Analysis Results

The calibration curve for voriconazole concentration in plasma is shown in Fig. 3, and the chromatograms for blank sample and each sample used for calibration are shown in Fig. 4.

Good linearity was obtained over the 0.1 to 10 μ g/mL range of concentration in plasma, with a correlation coefficient of 0.999 or higher.




Fig. 3 Voriconazole Calibration Curve

The accuracy and repeatability of each point on the calibration curve for voriconazole concentration in plasma is shown in Table 3.

Good results were obtained for all points on the calibration curve, with repeatability of 5 % or below and accuracy within 100 ± 10 %.

Table 3 Measurement Results of Standard Sample in Plasma

	Concentration in Plasma (µg/mL)	Accuracy (%)	Concentration Repeatability (%)
STD1	0.1	93.1	3.04
STD2	0.5	101.2	1.58
STD3	1	105.8	2.61
STD4	2.5	99.6	1.50
STD5	5	101.7	1.22
STD6	10	98.7	1.16

QC sample measurement results are shown in Table 4. The results obtained were sufficiently precise and accurate, with repeatability of 2 % or lower and concentration accuracy of 95 to 105 %.

Table 4 Measurement Results of QC Samples

	Concentration in	Accuracy	Concentration
	Plasma (µg/mL)	(%)	Repeatability (%)
QC 1	0.2	98.6	1.74
QC 2	4	103.6	1.56
QC 3	8	99.0	1.70




Fig. 4 Chromatograms for Samples with Voriconazole Spiked at Each Concentration in Plasma

This Application News was created with the cooperation of the Pharmaceutical Sciences Department of Tohoku University Hospital.

Notes: The products mentioned in this article have not received approval for use as medical devices based on the Pharmaceutical and Medical Device Act.

· The analytical methods mentioned in this article cannot be used for diagnostic purposes.

First Edition: May. 2016



Shimadzu Corporation www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedure

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, product/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation or its affiliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services. Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.